Investor Presentaiton
API: Continued strength in regulated markets
Key Updates
❖ Pricing pressures and currency challenges in some markets had an adverse impact on
demand
Regulated markets contribute ~72% of the revenue
* Strong portfolio- 8 fillings during the year. (5 USVMF + 3 CEPS)
API business now has total 29 USVMFS + 18 CEPS
New investment in capacity expansion for leading AH customers
* R&D capacity expansion
✰ Comprehensive margin and operations improvement program (Project Pragati )
underway. Benefits to kick in from Q2 FY 24.
1,072
J Sequent
Proven Ability In Life Sciences
ALIVIRA
Commercial
APIs
30+
Manufacturing
facilities
3
Revenues
All values in * Mn
4,565
4,004
4,314
R&D Centre
1
1,118
1,273
941
3,808
Q4 FY20 FY20
Q4 FY21 FY21
Q4 FY22 FY22
Q4 FY23 FY23
Sales to
Regulated
Markets
70%+
7View entire presentation